Coloplast AS's revenue for the
three
months ended in Mar. 2026 was $1,096 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $4,370 Mil.
Coloplast AS's Revenue per Share for the
three
months ended in Mar. 2026 was $4.87.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $19.40.
Warning Sign:
Coloplast AS revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Coloplast AS was 0.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Coloplast AS's highest 3-Year average Revenue per Share Growth Rate was 13.40% per year. The lowest was 3.60% per year. And the median was 7.70% per year.
Coloplast AS (OTCPK:CLPBF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Coloplast AS Revenue Related Terms
Coloplast AS Revenue Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Coloplast AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Revenue distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,370 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a Revenue of $4,370 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Revenue too high?
Coloplast AS's current Revenue is $4,370 Mil. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Revenue compare to ISRG and BDX?
Coloplast AS's Revenue of $4,370 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Coloplast AS and its competitors. Coloplast AS's current Revenue is $4,370 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.21, compared to a current price of $60.29 — trading 52.2% below its estimated fair value. The current Revenue is $4,370 Mil. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Revenue is $4,370 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $60.29 is trading 52.2% below its estimated GF Value™ of $126.21.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Revenue: $4,370 Mil
GF Value™: $126.21 vs. price of $60.29 (52.2% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
